Inclusion Body Myositis clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 40 years and up
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
San Francisco, California and other locations
Our lead scientists for Inclusion Body Myositis research studies include Laura Rosow, MD.